GCAM, Inc., headquartered in Fullerton, CA, was established in 2009 and a member of South Korea's GC grou...
LegoChem Biosciences has announced that it has entered a research collaboration and license agreement with Takeda Pharma...
PDC*line Pharma, a biotech company developing a new class of potent and scalable antigen presenting cell, based on a pro...
Samsung BioLogics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based i...
ACell, Inc. a leading regenerative medicine company, has recently announced that it has entered into an exclusive distri...
OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, has announced that it has signed a license and col...
ResMed, a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, has announced ...
The global healthcare and medical tourism conference "Medical Korea 2019" will be held for three days from March 14 at G...
Can-Fite BioPharma, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer...
WuXi Biologics a leading global open-access biologics technology platform company offering end-to-end solutions for biol...
Xynomic Pharma, a clinical stage US-China oncology drug development company, and Bison Capital Acquisition Corp.jointly ...
Enzychem Lifesciences, a global biopharmaceutical company headquartered in Seoul, Korea which is dedicated to developing...
According to reports from the Korean Herald, the government of Korea will spend 2.93 trillion won (US$2.61 billion...
ROKIT Healthcare, Inc., a regenerative medicine company focused on the development of novel regenerative therapeutic str...
SK Biopharmaceuticals and Arvelle Therapeutics GmbH have announced that they have entered into an exclusive licensing ag...
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the...
OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, has announced the nomination of OLX10020 as a clin...
Samsung Bioepis has announced that the U.S. Food and Drug Administration has approved ONTRUZANT, a biosimilar referencin...
